Your browser doesn't support javascript.
loading
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.
Hellmann, M D; Kim, T-W; Lee, C B; Goh, B-C; Miller, W H; Oh, D-Y; Jamal, R; Chee, C-E; Chow, L Q M; Gainor, J F; Desai, J; Solomon, B J; Das Thakur, M; Pitcher, B; Foster, P; Hernandez, G; Wongchenko, M J; Cha, E; Bang, Y-J; Siu, L L; Bendell, J.
Afiliación
  • Hellmann MD; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: hellmanm@mskcc.org.
  • Kim TW; Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, South Korea.
  • Lee CB; UNC Lineberger Comprehensive Cancer Center, Division of Hematology and Oncology, University of North Carolina at Chapel Hill, USA.
  • Goh BC; Department of Haematology-Oncology, National University Cancer Institute, Singapore, National University Hospital, Singapore.
  • Miller WH; Segal Cancer Center, Jewish General Hospital, Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Canada.
  • Oh DY; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
  • Jamal R; Department of Hematology-Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), University of Montreal, Montréal, Canada.
  • Chee CE; Department of Haematology-Oncology, National University Cancer Institute, Singapore, National University Hospital, Singapore.
  • Chow LQM; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle.
  • Gainor JF; Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, USA.
  • Desai J; Department of Medical Oncology, Royal Melbourne Hospital, University of Melbourne, Melbourne.
  • Solomon BJ; Department of Medical Oncology, Peter MacCallum Cancer Center, Melbourne, Australia.
  • Das Thakur M; Oncology Biomarker Development, Genentech, Inc., South San Francisco, USA.
  • Pitcher B; Biostatistics, Hoffmann-La Roche Ltd, Mississuaga, Canada.
  • Foster P; Product Development Oncology, Genentech, Inc., South San Francisco, USA.
  • Hernandez G; Oncology Biomarker Development, Genentech, Inc., South San Francisco, USA.
  • Wongchenko MJ; Oncology Biomarker Development, Genentech, Inc., South San Francisco, USA.
  • Cha E; Product Development Oncology, Genentech, Inc., South San Francisco, USA.
  • Bang YJ; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
  • Siu LL; Department of Medicine, Princess Margaret Cancer Centre-University Health Network, University of Toronto, Toronto, Canada.
  • Bendell J; Drug Development Unit Nashville, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA.
Ann Oncol ; 30(7): 1134-1142, 2019 07 01.
Article en En | MEDLINE | ID: mdl-30918950
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article